NTU Develops Novel 2-in-1 Biomarker and Drug Delivery System
Nanyang Technological University (NTU) has invented a unique biomarker with two exceptional functions.
First, it lights up when it detects tumour cells to allow scientists to take a better look. And it can also release anti-cancer drugs at the same time to the specific cells.
This new biomarker, which has immense potential for drug development, is made from a nanophosphor particle, ten thousand times smaller than a grain of sand.
NTU associate professors Zhang Qichun and Joachim Loo have found a way to make the nanoparticle light up when it is activated by near-infrared light emitted by an imaging device and only if tumour cells release small signalling molecules.
Prof Zhang said the use of near-infrared light, which is invisible to the human eye, is unique as most imaging techniques use ultraviolet light or visible light.
“Near-infrared light can penetrate 3–4 cm beyond the skin to deep tissue, much deeper than visible light. It also does not cause any damage to healthy cells, unlike ultraviolet or visible light,” added Prof Zhang, a materials expert.
“Visible light also causes photo bleaching, which is the destruction of the fluorescence dye that reduces the amount of time doctors and scientists have to image a tissue sample. Our new biomarker has effectively eliminated such key limitations which exist in existing biological markers.”
The breakthrough has resulted in two papers published in Small — a scientific journal for material science and nanotechnology.
Prof Loo said their new biomarker can also release anti-cancer drugs by creating a layer of coating loaded with drugs on the outside of the nanoparticle. The drugs are released when the biomarker lights up in response to the near-infrared light.
“This is the first time we are able to do bio-imaging, and potentially target the delivery of drugs at the same time, as proven in small animal tests,” said Prof Loo, a nanotechnology and bioimaging expert. “Our breakthrough will open up new doors in the various fields of nanomedicine, bioimaging and cancer therapeutics.”
The new biomarker also has other advantages. It has twice the contrast of conventional dyes and is able to emit up to three different colours of light. This means that it allows for better differentiation between healthy cells and tumour cells.
Unlike other new biomarkers used for imaging such as quantum dots, the NTU biomarker has also been shown to be non-toxic, staying in the body for up to two days before it is passed out harmlessly.
The team from NTU’s School of Materials Science and Engineering will be looking to load multiple layers of drugs into their biomarker. If successful, doctors will be able to release sequentially two or more drugs through the biomarker. This will benefit cancer patients as there will be fewer side effects due to the small doses administered and also higher efficacy as the biomarker has the ability to accurately target tumour cells.
The project, which took 3 years, is jointly funded by NTU, the Ministry of Education and the National Research Foundation, Singapore.
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance